Suppressor of Cytokine Signaling Mimetics as a Therapeutic Approach in Autoimmune Encephalitis

Autoimmune encephalitis (AE) is a debilitating neurological condition characterized by the immune system's attack on neuronal cells, often leading to significant cognitive and neurological impairments. Autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR), are linked to the disease. Additionally, cytokine dysregulation has been associated with heightened inflammatory responses in AE. Early intervention is critical for favorable outcomes. Recent findings have underscored the importance of suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1, in regulating cytokine signaling pathways and maintaining immune balance. SOCS1 mimetics in particular, designed to enhance SOCS1 activity, represent a novel therapeutic approach aimed at mitigating inflammation and promoting neuroprotection. This review underscores the intricate interactions between cytokines, SOCS family proteins, and the pathophysiology of AE, emphasizing the potential of SOCS1 mimetics and potentially other SOCS mimetics as a targeted treatment. This review also emphasizes the need for further research to validate the efficacy and safety of SOCS1 mimetics in clinical settings and their role in improving outcomes for patients with AE.